Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Florida
With
OneFlorida Clinical Research Consortium
The purpose of this research study is to develop pilot data to support a more precise way to treat high blood pressure based on an individual person's specific characteristics. Information from a blood test called plasma renin activity will be entered into an on-line app that may more precisely determine which medication should be used to treat high blood pressure than random selection. Renin is a substance in the body that is known to affect your blood pressure. By measuring plasma renin activity, and using that to select a blood pressure lowering medication it may help to more precisely select medications based on how an individual will respond.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
untreated HTN (systolic BP ≥ 140 or diastolic BP ≥ 90 mm Hg while taking no anti-HTN drugs)
treated, uncontrolled HTN (systolic BP ≥ 140 or diastolic BP ≥ 90 mm Hg while taking one or more anti-HTN drug)
provide voluntary, written informed consent
willing to comply with requirements of the study including provision of a blood sample for local laboratory determined PRA.
You may not be if
treated and controlled HTN (systolic BP \< 140 mm Hg and diastolic BP \< 90 mm Hg)
systolic BP ≥ 180 mm Hg or diastolic BP ≥ 110 mm Hg
secondary forms of HTN or any active, unstable disease process requiring new diagnostic and therapeutic plans
any life-threatening illness
history of alcohol or drug abuse in the past 5 years
mental illness or personality disorder that might interfere with adherence to study protocol
end-stage renal disease and progressive chronic kidney disease with serum creatinine \>2.5 mg/dl
intolerance to two or more classes of anti-HTN medications
